Background Type 2 diabetes mellitus (T2DM) is a condition characterized by insulin resistance and progressive failure of the insulin-secreting beta-cells. Based on studies in small cohorts of young patients (especially Pima Indian offspring), we know that individuals with childhood onset T2DM are at very high risk for diabetes-related morbidity and mortality, due to a longer life-time duration of diabetes, as well as possible increased rapidity of beta-cell failure. Our primary study objective is to acquire data on the natural history of T2DM in youth. Measurements will include indices of beta-cell function, body composition, cardiovascular disease risk factors, gut hormones, and psychological well-being. These data will be compared to findings in non-diabetic volunteers who are lean or overweight/obese. Data from several recent epidemiologic studies have indicated a link between diet soda consumption, obesity, and even type 2 diabetes. However, there is no evidence for a causal relationship. Artificial sweeteners have long been regarded as metabolically inert substances since they contain no or very few calories. Yet, data from rodent studies show that artificial sweeteners may have distinct effects on glucoregulatory hormones and our previous pilot study has confirmed a greater responsiveness of GLP-1 when a glucose meal was preceded by diet soda. We plan to further characterize effects of consumption of artificial sweeteners on intestinal and will enroll healthy volunteers, as well as subjects with type 1 and type 2 diabetes. These subjects will undergo repeated oral glucose tolerance tests or mixed meal tests, preceded by consumption of a water or a sucralose-containing diet soda. We will investigate differences in insulin, glucose, or other hormone levels between the repeated tests.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2011
Total Cost
$576,464
Indirect Cost
City
State
Country
Zip Code
Sanchez, Gina A Montealegre; Reinhardt, Adam; Ramsey, Suzanne et al. (2018) JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 128:3041-3052
Bauman, Viviana; Sturkey, Adaya C; Sherafat-Kazemzadeh, Rosa et al. (2018) Factitious hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 19:823-831
Blau, Jenny E; Bauman, Viviana; Conway, Ellen M et al. (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:
Gourgari, Evgenia; Dabelea, Dana; Rother, Kristina (2017) Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events? Curr Diab Rep 17:134
Brown, Rebecca J; Meehan, Cristina Adelia; Cochran, Elaine et al. (2017) Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab 102:1511-1519
Gourgari, Evgenia A; Mete, Mihriye; Sampson, Maureen L et al. (2017) Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes. Diabetes Care 40:e88-e89
Sylvetsky, Allison C; Issa, Najy T; Chandran, Avinash et al. (2017) Pigment Epithelium-Derived Factor Declines in Response to an Oral Glucose Load and Is Correlated with Vitamin D and BMI but Not Diabetes Status in Children and Young Adults. Horm Res Paediatr 87:301-306
Sylvetsky, Allison C; Edelstein, Sharon L; Walford, Geoffrey et al. (2017) A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes. J Nutr 147:2060-2066
Blau, Jenny E; Tella, Sri Harsha; Taylor, Simeon I et al. (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev 33:
Brown, Rebecca J; Araujo-Vilar, David; Cheung, Pik To et al. (2016) The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 101:4500-4511

Showing the most recent 10 out of 42 publications